Silexion Therapeutics Stock Plunges 11.45% on Warrant Exercise

On August 1, 2025, Silexion's stock experienced a significant drop of 11.45% in pre-market trading, reflecting a notable shift in investor sentiment.

Silexion Therapeutics recently announced the exercise of new warrants, with an exercise price set at $11.32 per share. This move is part of the company's strategy to strengthen its financial position and support the development of its RNAi therapy for KRAS-driven cancers.

The company's stock has seen volatility due to the release of new preclinical data, which showed inhibition rates of up to 97% in pancreatic cancer cells. This positive data has contributed to a surge in the stock price, reaching a multi-year high of $22.36. The market capitalization of Silexion Therapeutics stands at approximately $9.64 million, positioning it as a small-cap entity in the competitive biotech landscape.